The standard nasal cannula and separate bite block delivers oxygen to the nose only, or at most also to the front of the mouth in specialty systems. Oral breathing is more common when a patient is sedated, so nasal delivery has limited FiO2 potential. Any oxygen delivered to the front of the mouth is diluted and is also limited. AIM delivers oxygen directly to the posterior pharynx from inside the mouth so FiO2 saturation can be maintained. AIM delivered greater than 96% FiO2 at 14 LPM while simultaneously providing reliable end-tidal CO2 waveforms through an integrated sampling port.
No. AIM is designed for full oral cavity access throughout your procedure. The low-profile footprint is similar to some unilateral dental bite blocks that only take up space between the molars on one side of the mouth but do not extend to the center. AIM does not obstruct scope passage during upper endoscopy, TEE, or other oropharyngeal procedures. The oxygen and CO2 sampling lines route away from the procedural field. Clinicians have reported that scope placement with AIM is easier than with standard oxygen delivery and bite blocks.
Direct pharyngeal oxygenation means oxygen is delivered from inside the oral cavity to the posterior pharynx, the anatomical space immediately above the airway opening. This enables standard oxygen flow to deliver very high FiO2 levels because it is not diluted in the mouth or nasal cavity. Mouth breathing is most common in sedated patients, so nasal delivery can be unreliable and limit maximum FiO2. Pharyngeal delivery overcomes this limitation and is particularly effective in obese patients, oral breathers, and cases where nasal airflow is compromised.
Yes. AIM is an FDA-cleared Class II medical device indicated for use during procedures requiring sedation. Clinicians have reported successful use in ASA III and IV patients, including morbidly obese patients and those with elevated desaturation risk. The no-gag design allows oxygenation to begin before sedation induction and to continue through recovery.
Some high-risk sedation cases require conversion to GA (extreme pain, patient movement, or respiratory compromise). Traditionally, this requires removing the oxygen delivery device, having someone hold the breathing mask on the patient's face, administering the drugs, prying the jaw open, and securing the airway. The many steps cause delay, workflow disruption, and occasionally oxygen interruption. With AIM, you can increase oxygen flow and secure the airway through the open mouth without assistance or delay to the procedure.
AIM connects to standard wall oxygen or cylinder oxygen sources using a conventional oxygen supply line. No specialized equipment or capital investment is required. The CO2 sampling port connects to any standard capnography monitor via a conventional sampling line. AIM is designed to integrate with the anesthesia monitoring systems already in use at your facility.
The beauty of AIM is in its simplicity! AIM is placed and connected in under one minute by any trained anesthesia provider. The workflow mirrors a standard bite block: connect the oxygen supply and CO2 sampling lines, then insert intraorally. See the IFU for full details.
Yes. AIM is MRI Safe and cleared for use in MRI suite environments, including sedated scans and interventional MRI procedures. No metal components are present that would create a safety hazard in the MRI environment.
AIM is FDA-cleared for procedures requiring sedation across a wide range of clinical settings. For office-based procedures using IV moderate sedation including cosmetic surgery and minor orthopedic cases, AIM provides the same pharyngeal oxygenation and CO2 monitoring capability as hospital and ASC environments. Contact us to discuss your specific procedural setting.
AIM is a single-use disposable device. Contact our team for current per-unit pricing and volume discount information.
AIM is a Class II device cleared for use by the FDA. Clinical experience includes reported FiO2 maintenance at 100% in morbidly obese patients, reliable EtCO2 waveforms across GI and cardiac procedural settings, and no interference with procedural access during endoscopy.
Yes. AIM eliminates the need for separate endoscopy bite blocks and awake fiberoptic intubation airways in many cases.
Yes. By reducing hypoxic events and airway rescue interventions, AIM may reduce adverse events and related costs.
Yes. AIM is particularly beneficial in high-volume ASC environments.
Don't see your question here? Our team is happy to answer clinical, technical, or procurement questions directly.
Contact Us